Unknown

Dataset Information

0

Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort.

ABSTRACT:

SUBMITTER: England JT 

PROVIDER: S-EPMC9162913 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Management of challenging myelofibrosis after JAK inhibitor failure and/or progression.
| S-EPMC8895349 | biostudies-literature
Unknown The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes.
| S-EPMC9324085 | biostudies-literature
Unknown TET2 rs1548483 SNP Associating with Susceptibility to Molecularly Annotated Polycythemia Vera and Primary Myelofibrosis.
| S-EPMC7711989 | biostudies-literature
Unknown Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis.
| S-EPMC7464183 | biostudies-literature
Unknown JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis.
| S-EPMC9138443 | biostudies-literature
Unknown Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis.
| S-EPMC6261652 | biostudies-literature
Unknown Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.
| S-EPMC12092244 | biostudies-literature
Unknown Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis.
| S-EPMC6426689 | biostudies-literature
Unknown Long-term stability and reusability of molecularly imprinted polymers.
| S-EPMC5361172 | biostudies-literature
Unknown Molecularly Tailored Interface for Long-Term Xenogeneic Cell Transplantation.
| S-EPMC10622113 | biostudies-literature